Compare DHT Holdings Inc. (DHT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DHT Holdings Inc. vs TG Therapeutics Inc — how do they compare? DHT Holdings Inc. trades at $24.85 (market cap $4.02B), while TG Therapeutics Inc trades at $53.06 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 2× DHT Holdings Inc.'s market cap, and DHT Holdings Inc. pays a 19.57% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DHT Holdings Inc. for 0 Days and TG Therapeutics Inc for 15 Days on average.
| DHT | TGTX | |
|---|---|---|
Market Cap | $4.02B | $8.16B |
Volume | 5,493,801 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $24.93 | $59.06 |
52-Week Low | $11.20 | $26.94 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $4.29B | $8.37B |
Dividend Yield | 19.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $52.95, up 1.46% on the day, with a bearish technical signal from moving averages despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29 million and net income of $447.18 million, though recent quarterly EPS results have missed expectations. Analyst sentiment remains largely positive, with an 84.62% buy rating and a consensus price target of $80.50, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook for TGTX is mixed, with robust revenue guidance and product momentum offset by earnings misses and negative cash flow. Key opportunities include BRIUMVI's expanding market share and potential buyout speculation, but risks involve ongoing legal scrutiny, competitive pressures, and the need to translate top-line growth into consistent bottom-line performance amid significant cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DHT Holdings Inc.
DHT Holdings operates a fleet of crude oil tankers that trade on international routes. Its fleet consists of very large crude carriers, or VLCCs.
Read more on DHT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
